Biopharmaceutical Leader
Strategy • Commercial Insights • Marketing
I help biopharma companies turn promising science into commercial success — from early pipeline through launch and beyond. Today, I do this through Ajae Biopharma Consulting and as an advisor to the Healthcare Shares VC Fund.
With 15+ years spanning industry and academia, I have worked at the intersection of science and business — helping organizations navigate complex therapeutic landscapes, make smarter investment decisions, and bring transformative medicines to the patients who need them.
My approach combines deep scientific understanding with commercial rigor. Whether it is shaping a launch strategy for a first-in-class biologic, building a competitive intelligence function from the ground up, or advising early-stage healthcare ventures through Ajae Biopharma Consulting, I focus on one thing: translating data into decisions that matter.
From pipeline to post-launch, I build insight-driven strategies that connect R&D ambition with commercial reality — helping leadership teams prioritize, invest, and win across therapeutic areas.
I design and lead primary and secondary research programs that go beyond data collection — delivering the kind of actionable intelligence that shapes portfolio decisions and executive strategy.
New product planning, portfolio governance, opportunity assessments, financial valuation, and lifecycle management that secure leadership buy-in and investment
End-to-end CI programs — from playbook development and landscape monitoring to congress coverage and real-time competitive signal tracking
Designing fit-for-purpose primary and secondary research, forecasting, and analytics programs that turn complex data into clear strategic direction
Building alignment across R&D, medical, regulatory, access, and commercial teams — including multi-company partnerships and executive-level presentations
Deep experience across Oncology, Immunology, Cardio-Metabolic, Neurology, and Respiratory — from early pipeline through commercial lifecycle
Orchestrating global launch campaigns — branded and unbranded, multichannel execution, market access strategy, and HCP/patient education programs
A decade-plus journey across the biopharma value chain — from competitive intelligence to global marketing to strategic advisory.
Ajae Biopharma Consulting & Healthcare Shares VC Fund
Through Ajae Biopharma Consulting, I advise biopharma companies and healthcare investors on commercial strategy, insights generation, and new product planning. I also serve as an advisor to the Healthcare Shares VC Fund, evaluating early-stage investment opportunities and providing due diligence that bridges the gap between investor thinking and operational reality.
Seagen (acquired by Pfizer)
Led a team of six insights professionals overseeing market research, competitive intelligence, and forecasting across the entire oncology portfolio. When Pfizer acquired Seagen, I spearheaded the insights integration — migrating archives, research, and intelligence systems while identifying gaps and establishing new processes for the combined organization. I also authored the CI playbook that became the standard operating framework across the team.
Amgen
A dual role that stretched across two distinct mandates. On the strategy side, I led commercial assessments for the cardio-metabolic and autoimmune pipeline, ultimately securing CEO-level portfolio governance approval for a high-priority Phase III and launch investment. On the marketing side, I served as global marketing lead for the joint Amgen & AstraZeneca Tezspire™ launch — directing agencies across both companies to build the multichannel campaign, branded HCP messaging, device training programs, and lifecycle strategy that brought the product to market.
Amgen
Oversaw global and US competitive intelligence across four therapeutic areas, managing an annual budget exceeding $1M. This is where I built the connective tissue between insights and action — synthesizing intelligence across 10+ pipeline, inline, and biosimilar assets to inform marketing, market access, clinical, and business development strategies. Key highlights include developing the competitive readiness playbook for the Aimovig™ Japan launch and driving cross-functional alignment on the EVENITY® US pricing and access strategy.
Amgen (via 3 Key Consulting)
This is where the biopharma journey began. I built the oncology early-pipeline CI function from scratch, covering 15+ assets across a rapidly evolving immuno-oncology landscape. Over three years, I delivered quarterly strategic recommendations to commercial, R&D, business development, and corporate strategy leadership. I led several first-of-their-kind initiatives at Amgen, including the company's inaugural CAR-T asset plan, a tumor-agnostic development framework, and a China commercial strategy.
Stanford University, CA
Keck Graduate Institute, Claremont, CA
Business Administration Certificate
University of California, Irvine, CA
Vellore Institute of Technology, India
Whether you are exploring a strategic challenge, evaluating an opportunity, or simply want to exchange ideas — I would love to hear from you.